Can you take semaglutide and tirzepatide together?

Do these two medicines work the same way?

Not quite. Semaglutide (sold as Wegovy for weight management) is a GLP-1 receptor agonist. It mimics a gut hormone released after eating, slowing gastric emptying and reducing appetite through one signalling pathway. Tirzepatide, sold as Mounjaro, does the same thing and also activates GIP receptors, making it the only dual-agonist weight-loss medicine currently licensed in the UK. Whether that second pathway meaningfully changes real-world outcomes for any given person is a question a prescriber works through with you.

Because both drugs target appetite and food intake through related mechanisms, running them in parallel would not simply add their effects. If you are wondering whether you can take Mounjaro and Wegovy together, the short answer is that the safety and efficacy of semaglutide and tirzepatide taken together has not been studied in clinical trials, and no prescriber acting within current UK guidance would recommend it. If you have read about combining them elsewhere, the source is not a licensed clinical protocol.

The NHS provides a clear overview of how each medicine works: see the NHS patient guide to tirzepatide and the NHS patient guide to semaglutide for the authoritative plain-English explanations. For a detailed side-by-side comparison of these two medicines, our Wegovy vs Mounjaro overview covers the practicalities.

What does the clinical trial evidence show for each one separately?

Both have strong evidence, but the numbers differ. In the SURMOUNT-1 trial, participants using tirzepatide 15mg lost around 20–21% of body weight on average over 72 weeks. Semaglutide 2.4mg produced around 15% average loss over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. The SURMOUNT-5 head-to-head trial (72 weeks, published in NEJM 2025) found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg in adults with obesity and no diabetes.

A newer semaglutide dose, 7.2mg, approved by the MHRA in January 2026 and available as a single-dose pen from April 2026, has shown around 20.7% average loss in trials, narrowing the gap with tirzepatide's highest dose considerably. Neither medicine guarantees a specific result for any individual; response varies, and both work alongside reduced-calorie eating and increased activity.

The table below summarises the key factual differences.

NICE's appraisals are worth reading directly: TA1026 for tirzepatide sets out the recommended BMI thresholds and qualifying conditions in detail.

Who qualifies for each medicine under UK private prescribing?

The licensed eligibility criteria are similar but not identical. Both medicines are approved for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

What differs is the NICE-recommended NHS pathway. Tirzepatide is recommended under TA1026 for adults with a BMI of 35 or more plus at least one weight-related comorbidity, within a phased NHS rollout. Semaglutide is recommended under TA875 for up to two years within specialist weight management services. Private prescribing at nume follows the licensed criteria rather than the NHS-commissioned thresholds, so eligibility is wider, but the prescriber still assesses every application individually. BMI alone is never the whole picture.

If you are weighing up which medicine to pursue, our comparison of Mounjaro, Wegovy and Saxenda walks through the decision factors in more detail, and our treatment overview sets out what is available through nume right now.

Is taking Mounjaro and semaglutide together ever clinically justified?

No prescriber working within UK licensed guidance would prescribe Mounjaro and semaglutide together as a weight-loss regimen. The question comes up (our prescribers hear it fairly regularly) usually from people who have read anecdotal accounts online or who have plateaued on one medicine and wonder whether adding the other would help. The honest answer is that we do not have trial data on the combination, the theoretical risk of additive side effects is real, and the licensed route is always one medicine at a time.

If your current treatment has stopped producing results, that is a genuine clinical conversation worth having. Dose titration, medicine switching, or reviewing lifestyle factors alongside treatment are all evidence-based options. The detailed page on taking tirzepatide and semaglutide together covers the safety reasoning in full. If you are already on one medicine and wondering about switching rather than combining, our guide on whether you can use Mounjaro and Wegovy together addresses the transition question directly.

Which medicine suits you is a clinical decision our prescribers make with you, based on your health history, current medicines and treatment goals, and if you are still weighing up whether semaglutide or tirzepatide is the right fit, our dedicated comparison page works through the key considerations. Speak to our prescribers through a free consultation, same day, no referral needed, no waiting list.